Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A-Reference-Cited by-同舟云学术

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Published:2015-07-27 Issue:1 Volume:22 Page:72-80
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Nolan B.¹,Mahlangu J.²,Perry D.³,Young G.⁴,Liesner R.⁵,Konkle B.⁶,Rangarajan S.⁷,Brown S.⁸,Hanabusa H.⁹,Pasi K. J.¹⁰,Pabinger I.¹¹,Jackson S.¹²,Cristiano L. M.¹³,Li X.¹³,Pierce G. F.¹³,Allen G.¹³

Affiliation:

1. Our Lady's Children's Hospital Dublin Ireland

2. University of the Witwatersrand Faculty of Health Sciences Johannesburg South Africa

3. Addenbrookes Hospital Cambridge UK

4. Children's Hospital Los Angeles University of Southern California Keck School of Medicine Los Angeles CA USA

5. Great Ormond Street Hospital London UK

6. Puget Sound Blood Center Seattle WA USA

7. Basingstoke and North Hampshire Hospital Basingstoke UK

8. Lady Cilento Children's Hospital Brisbane Qld Australia

9. Ogikubo Hospital Tokyo Japan

10. Barts and the London Comprehensive Care Center London UK

11. Medizinsche Universitat Wien Vienna Austria

12. St Paul's Hospital Vancouver BC Canada

13. Biogen Cambridge MA USA

Funder

Biogen

Bayer

CSL Behring

Novo Nordisk

Baxter International

Pfizer

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12766

Reference15 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. National Hemophilia Foundation.Medical and Scientific Advisory Council (MASAC) recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding) 2007. Available athttp://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed May 28 2015

3. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

4. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

5. Barriers to compliance with prophylaxis therapy in haemophilia

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand;Research and Practice in Thrombosis and Haemostasis;2023-08

2. New directions to develop therapies for people with hemophilia;Expert Review of Hematology;2023-03-08

3. Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy;International Journal of Hematology;2022-12-04

4. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies;Research and Practice in Thrombosis and Haemostasis;2022-07

5. LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A;Haemophilia;2022-05-13